CERC Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Aug 2021 @ 00:00):

Stats
Today's Volume	258 592
Average Volume	639 167
Market Cap	38.63M
EPS	$-0.180 ( 2021-08-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.38
ATR14	$0.168 (5.73%)

Insider Trading

Date	Person	Action	Amount	type
2021-08-18	Armistice Capital, Llc	Buy	20 000	Common Stock
2021-08-16	Armistice Capital, Llc	Buy	30 000	Common Stock
2021-07-01	Cola Michael F	Buy	51 740	Stock Option (Right to Buy)
2021-06-30	Bruhn Suzanne Louise	Buy	3 465	Stock Option (Right to Buy)
2021-06-30	Kaplan Gilla	Buy	6 353	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 95 transactions
Buy: 9 414 351 \| Sell: 408 195

Volume Correlation

Long: -0.09 (neutral)

Short: 0.16 (neutral)

Signal:(52.235) Neutral

Cerecor Inc Correlation

10 Most Positive Correlations
CIDM	0.862
FRAF	0.858
MLVF	0.857
EM	0.835
CLDX	0.834
BWAY	0.834
CAMP	0.826
GLMD	0.826
IMVT	0.824
BLI	0.816

10 Most Negative Correlations
RMRM	-0.941
DBX	-0.92
PTC	-0.911
PCT	-0.898
DUSA	-0.894
DWUS	-0.89
DEMZ	-0.889
PSET	-0.888
EXPI	-0.885
SAMG	-0.883

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cerecor Inc Correlation - Currency/Commodity

0.30
( neutral )

0.19
( neutral )

0.00
( neutral )

0.43
( neutral )

0.59
( weak )

-0.56
( weak negative )

Financial Reports:

No articles found.

Cerecor Inc

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.